Company Description
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes.
The company’s technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes.
Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form.
The company’s lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
Its three lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation.
The company’s diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas.
In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body’s immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.
It has research agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive.
Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
| Country | United States |
| Founded | 2009 |
| IPO Date | Mar 29, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 15 |
| CEO | Ryan Confer |
Contact Details
Address: 3300 Bee Cave Road, Suite 650-227 Austin, Texas 78746 United States | |
| Phone | 877 774 4679 |
| Website | genprex.com |
Stock Details
| Ticker Symbol | GNPX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001595248 |
| CUSIP Number | 372446104 |
| ISIN Number | US3724462037 |
| Employer ID | 90-0772347 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Ryan M. Confer M.S. | President, Chief Executive Officer, Chief Financial Officer and Director |
| Dr. Mark S. Berger M.D. | Chief Medical Officer |
| David M. Schloss | Senior Vice President of Human Resources |
| Thomas C. Gallagher Esq. | Senior Vice President of Intellectual Property and Licensing |
| Dr. Suzanne Thornton-Jones Ph.D. | Senior Vice President of Regulatory Affairs and Quality |
| Celina Laney | Chief of Staff |
| Dr. Jack A. Roth F.A.C.S., M.D. | Chairman of Scientific and Medical Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 16, 2025 | EFFECT | Notice of Effectiveness |
| Sep 16, 2025 | 424B3 | Prospectus |
| Sep 12, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Sep 5, 2025 | DRS | [Cover] Draft Registration Statement |
| Aug 20, 2025 | 8-K | Current Report |
| Aug 18, 2025 | 8-K | Current Report |
| Aug 15, 2025 | 8-K | Current Report |
| Aug 14, 2025 | 10-Q | Quarterly Report |
| Aug 5, 2025 | RW | Filing |
| Aug 4, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |